PainReform

Update in progress

PRFX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

PRF Technologies Ltd. is a specialty pharmaceutical company in Israel focused on reformulating established therapeutics. It develops OcuRing-K, a bio-erodible sustained‑release implant placed on the haptic of an intraocular lens for cataract surgery, and PRF-110, a viscous oil‑based solution instilled into the surgical wound to provide localized, extended postoperative analgesia. Formerly PainReform Ltd, it renamed to PRF Technologies Ltd in January 2026. Founded in 2007 and based in Tel Aviv-Yafo.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.24; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive